Immunotherapeutic methods using irreversible electroporation
Methods for treating tissue with irreversible electroporation and immunotherapy are described. The methods include placing a probe in tissue within a human body, wherein the probe has at least a first electrode, applying a plurality of electrical pulses through the first electrode and a second electrode, causing irreversible electroporation (IRE) of the tissue within a target ablation zone, and administering one or more exogenous agents into the tissue within the target ablation zone or to the human, thereby stimulating or otherwise modulating an immune system response within the body.
1. A method for treating tissue comprising:
placing a probe in tissue within a human body, wherein the probe has at least a first electrode;
applying a plurality of electrical pulses through the first electrode and a second electrode, wherein the electrical pulses are applied with:
a pulse length of between 1 picosecond 100 microseconds;
a frequency of 10-100 kHz; and
a delay between two adjacent pulses; and
causing irreversible electroporation (IRE) of cells within a target ablation zone in a manner and in an amount sufficient to promote an immune response that causes death of metastases by way of immune cells that respond to tissue injury resulting from the IRE.
2. The method of claim 1 , wherein the electrical pulses have a pulse length of between 1 picosecond-10 microseconds.
3. The method of claim 1 , wherein the electrical pulses are applied at a voltage of about 500-10,000 V.
4. A method for treating tissue comprising:
placing a probe in tissue within a human body, wherein the probe has at least a first electrode;
applying a plurality of electrical pulses through the first electrode and a second electrode, wherein the electrical pulses are applied with:
a pulse length of 1 second or less;
a frequency of 10-100 kHz; and
a delay of up to 5 times the pulse length between two adjacent pulses;
causing irreversible electroporation (IRE) of cells within a first zone; and
promoting an immune response in a manner that causes death of metastases by way of immune cells that respond to the applied electrical pulses.
5. The method of claim 4 , wherein the immune response is promoted by immune cells present in the first zone, which is a target ablation zone.
6. The method of claim 4 , wherein the immune response is promoted by immune cells present in a second zone, which is a zone disposed beyond the first zone.
7. The method of claim 5 , wherein the immune response is promoted by immune cells present in the first zone and a second zone, wherein the second zone is disposed beyond the target ablation zone.
8. The method of claim 4 , wherein the electrical pulses have a pulse length of 100 microseconds or less.
9. The method of claim 4 , wherein the electrical pulses have a pulse length of 10 microseconds or less.
10. The method of claim 4 , wherein the electrical pulses have a pulse length of 5 microseconds or less.
11. A method for treating tissue comprising:
placing a probe in tissue within a human body, wherein the probe has at least a first electrode;
applying a plurality of electrical pulses through the first electrode and a second electrode, wherein the electrical pulses are applied with:
a voltage of at least 500 V;
a frequency of 10-100 kHz;
a pulse length of 100 microseconds or less; and
a delay between two adjacent pulses; and
causing a combination of electroporation-based therapy (EBT) and irreversible electroporation (IRE) of cells within a first zone, which is a target ablation zone, and in a manner and in an amount sufficient to promote an immune response that causes death of metastases by way of immune cells that respond to tissue injury resulting from the IRE.
12. The method of claim 11 , wherein the electroporation-based therapy (EBT) is reversible electroporation.
13. The method of claim 12 , wherein the EBT is electrochemotherapy (ECT).
14. The method of claim 12 , wherein the EBT is electrogenetherapy (EGT).
15. The method of claim 11 , wherein the method further comprises the steps of:
delivering an agent after applying the electrical pulses to cause IRE of the cells; and
delivering electrical pulses to cause reversible electroporation after delivering the agent.
16. The method of claim 15 , wherein the agent comprises a small molecule.
17. The method of claim 15 , wherein the agent comprises a nucleic acid.
18. The method of claim 11 , wherein the method further comprises the steps of:
delivering an agent to a second zone, which is a zone disposed beyond the target ablation zone; and
allowing the agent to be taken up by cells within the second zone.
19. The method of claim 18 , wherein the agent comprises a small molecule.